NetworkNewsBreaks – InMed Pharmaceuticals Inc. (
Post# of 228
(Total Views: 131)
Posted On: 04/04/2024 4:32:07 PM
NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Favorable Results from INM-901 Preclinical AD Studies
InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting additional preclinical data demonstrating the positive effects of its INM-901 for the potential treatment of Alzheimer’s disease (“AD”). Highlights of the report note that INM-901 receptor binding studies indicate preferential signaling agonism for both cannabinoid 1 (“CB1”) and cannabinoid 2 (“CB2”) and impacts the peroxisome proliferator-activated receptors (“PPAR”) signaling pathway while in vivo studies demonstrate INM-901 reduces neuroinflammation and improves neuronal function. In addition, molecular analysis data explains previously reported observations in behavioral studies on locomotion, memory and cognition. According to the announcement, several preclinical studies were conducted in well-characterized AD models and the company plans to accelerate the development of its AD program. “The recent results demonstrating pharmacological effects in in vivo disease models continue to validate INM-901 as a potential treatment of AD,” said InMed senior vice president of preclinical research and development Dr. Eric Hsu in the press release. “We are particularly encouraged with indications that INM-901 has multiple potential mechanisms of action as a preferential signaling agonist for both cannabinoid 1 and cannabinoid 2 receptors, as well as impacting the peroxisome proliferator-activated receptor signaling pathway. There continues to be a major unmet medical need for this multi-factorial disease and differentiated therapeutic mechanisms may play an important role. We believe the development of INM-901 may address several pathological factors including neuroinflammation, neuroprotection and neuritogenesis.”
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting additional preclinical data demonstrating the positive effects of its INM-901 for the potential treatment of Alzheimer’s disease (“AD”). Highlights of the report note that INM-901 receptor binding studies indicate preferential signaling agonism for both cannabinoid 1 (“CB1”) and cannabinoid 2 (“CB2”) and impacts the peroxisome proliferator-activated receptors (“PPAR”) signaling pathway while in vivo studies demonstrate INM-901 reduces neuroinflammation and improves neuronal function. In addition, molecular analysis data explains previously reported observations in behavioral studies on locomotion, memory and cognition. According to the announcement, several preclinical studies were conducted in well-characterized AD models and the company plans to accelerate the development of its AD program. “The recent results demonstrating pharmacological effects in in vivo disease models continue to validate INM-901 as a potential treatment of AD,” said InMed senior vice president of preclinical research and development Dr. Eric Hsu in the press release. “We are particularly encouraged with indications that INM-901 has multiple potential mechanisms of action as a preferential signaling agonist for both cannabinoid 1 and cannabinoid 2 receptors, as well as impacting the peroxisome proliferator-activated receptor signaling pathway. There continues to be a major unmet medical need for this multi-factorial disease and differentiated therapeutic mechanisms may play an important role. We believe the development of INM-901 may address several pathological factors including neuroinflammation, neuroprotection and neuritogenesis.”
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)